1.. Background {#s6}
==============

Although linkage studies suggested that genetic factors play a major role in the onset and course of schizophrenia, the exact mechanisms remain unclear.[@B1] One gene of particular interest is *ANK3* , located on chromosome 10q21. It acts on the early development of the Ranviers nodes of axonsin the central and peripheral nervous systems[@B2] and, thus, plays a key role in the regulation and differentiation of the nervous system.[@B4] When the *ANK3* gene is knocked out in mice, the mice show abnormal hypothalamic - pituitary - adrenal axis (HPA) functioning.[@B4] Ankyrin G (ANKG), which is encoded by the *ANK3* gene, is crucial for the stability of the neuronal membrane[@B5],[@B6] and facilitates the connection between axons and ribbon synapses.[@B7] ANKG also regulates ion channels involved in the release of neurotransmitters;[@B8] abnormal expression of ANKG may induce abnormal activity in glutamate receptors (GluRs).[@B9] Many studies have demonstrated that abnormal release of brain neurotransmitters in different neural pathways is involved in the pathogenesis of schizophrenia. Thus, HPA axis dysfunction and abnormal glutamate activity-- both of which are influenced by *ANK3* -- are key targets in the search for the genetic causes of schizophrenia.

Several studies suggest that *ANK3* is important in the pathogenesis of schizophrenia. Athanasiu and colleagues conducted a genome-wide association study (GWAS) in 2663 European individuals with schizophrenia and 13,780 controls and reported that the *ANK3* gene rs10761482 polymorphism was associated with schizophrenia.[@B10] Yuan and colleagues found the same results in a sample of Han Chinese.[@B11] Another study reported that the *ANK3* was also related to the age of onset of schizophrenia.[@B12] In this study, we aim to assess the relationship of the *ANK3* rs10761482 polymorphism with schizophrenia among individuals of Uyghur decent (one of China's large ethnic minority groups) living in the Xinjiang region of western China and determine whether or not the polymorphism is different in persons with schizophrenia who have an early versus late age of onset.

2.. Methods {#s7}
===========

2.1. Sample {#s7a}
-----------

Figure 1 shows the enrollment process for the study. All the participants were natives to Xinjiang of the Uyghur nationality and had no biological connections with each other. Two senior psychiatrists conducted the diagnosis and collected the clinical data in the patient group. We provided a detailed explanation to all participants about the purpose of this study and obtained informed consent signed by the subjects or their guardians. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University.

![Identification of study participants](sap-26-05-288-g002){#sap-26-05-288-g002.tif}

### 2.1.1. Case group {#s7aa}

A total of 649 Uyghur inpatients diagnosed with schizophrenia were recruited from six hospitals in the Xinjiang Uyghur Autonomous Region of China between January 2011 and May 2013: the Department of Psychology of the First Affiliated Hospital of Xinjiang Medical University, the Urumqi Peace Hospital, the Hotan Mental Health Hospital, the Kashgar First People's Hospital, the Yili Mental Health Hospital, and the Aksu Prefecture Kangning Hospital. Inclusion criteria were: (a) 20 to 80 years of age; (b) diagnosis of schizophrenia based on the criteria specified in the Diagnostic and Statistical Manual of Mental Disorders 4^th^ edition (DSMIV) as assessed by two trained psychiatrists using the Chinese version of the Structured Clinical Interview for DSM-IV (SCID)[@B13] ; (c) no mental retardation or other mental disorders; (d) no family history of mental illnesses; (e) no central nervous system diseases or traumatic brain injury; and (f) no serious physical illnesses, such as cancer, endocrine disease, severe cardiovascular disease, or liver or kidney dysfunction.

The 649 patients in the case group included 389 (60%) males and 260 (40%) females. Their mean (sd) age was 44.4 (12.1) years. Among them, 134 (75 males and 59 females) had the first onset of illness when they were 18 years of age or younger (the 'adolescent-onset' group); the remaining 515 (314 males and 201 females) had the first onset after 18 years of age (the 'adult-onset' group).

### 2.1.2. Control group {#s7ab}

Individuals of the Uyghur minority who participated in a routine physical examination at the First Affiliated Hospital of Xinjiang Medical University from May 2012 to May 2014 were potential control subjects. They had to meet the same inclusion criteria as the case group (above) except that they had no present or prior history of mental disorders. Potential participants were administered the Composite International Diagnostic Interview (CIDI)by psychology research fellows to identify those with current or past mental illnesses. A total of 557 control subjects participated in the study, including 303 (54%) malesand 254 (46%) females. Their mean age was 45.1 (15.50) years.

There was a borderline excess of males in the case group compared to the control group (60% vs. 54%; *χ*^2^=3.76, *p*=0.052) but there was no significant difference in the mean age of the two groups (*t*=0.82, *p*=0.414).

2.2. Genotype assessment {#s7b}
------------------------

Two milliliters of venous blood was drawn from each participant.Blood samples were prepared for genotyping using the DNA extraction system provided by the Tiangen Biotech Company in Beijing.

Based on findings from previous GWAS studies, we selected the loci rs10761482 of the *ANK3* gene for genotyping.According to the PubMed nucleic acid database, the rs10761482 (C/T) is in the first intron of the *ANK3* gene in Asian and European populations and the allele frequencies were greater than 0.1.

Taqman probe-based polymerase chain reaction (PCR)was used for genotyping. PCRwas conducted using the GeneAmp PCR 9700 system (Applied Biosystem). Each well of the 384-well plate contains 5μl of PCR reaction material: 40ng DNA, 2.5μl PCR reaction mixture, and 0.035μl Taqman probes.Forty five cycles of amplification were performed using the following settings: 95°C for 10 minutes, 92°C for 15 seconds, and 60°C for 1 min. The product was genotyped using the ABI 7900 DNA detection system (Applied Biosystem, Foster City, CA, USA). In the patient group 97.1% (630/649) of the samples were successfully genotyped; in the control group 96.1% (535/557) were successfully genotyped. In order to ensure accuracy and reliability, we randomly selected 3% of the samples from each of the two groups to genotype again; the same results were obtained from all of these re-tested samples.

2.3. Statistical Analysis {#s7c}
-------------------------

Microsoft Excel was used to construct the database. SPSS17.0 software was used for analysis. Two-sample t-test was used to compare the age of onset and *χ*^2^ test was used to compare the male-female ratios. In addition,the SHEsis software (<http://analysis.bio-x.cn>) was used to test if the data were in accordance with the Hardy-Weinberg equilibrium (HWE) and to analyze differences in the allele frequencies and genotypes between the two groups. Due to the borderline difference in the male-female ratios between the two groups, we also conducted a stratified analysis by gender.

3.. Results {#s8}
===========

3.1. Comparisons of the allele and genotype frequencies between the case group and control group {#s8a}
------------------------------------------------------------------------------------------------

The distribution of the rs10761482 polymorphisms met the Hardy-Weinberg equilibrium (HWE) requirements in all four subgroups of subjects considered in this analysis: male cases (*p*=0.059), male controls (*p*=0.116), female cases (*p*=0.956), and female controls (*p*=0.855). No statistically significant differences were found in the rs10761482 allele and genotype frequencies between the 630 cases and 535 controls who were successfully genotyped. As shown in Table 1, similar results were found when the analysis was stratified by gender; neither the allele frequency nor the genotype frequency were significantly different between male cases and controls or between female cases and controls.

Separate comparison of the results of the 381 males with schizophrenia who were successfully genotyped and the 249 females with schizophrenia who were successfully genotyped found no significant difference by gender in the allele frequency (*OR*=1.01, *CI*=0.77\~1.33, *p*=0.942) or in the genotype frequency (*χ*^2^=1.52, *p*=0.468).

###### 

Comparisons of allele and genotype frequencies of the ANK3gene rs10761482 polymorphism between persons of Uyghur nationality with and without schizophrenia

  rs10761482         Allele       Genotype                                                                                           
  ------------------ ------------ ------------ ------------ ---------------- ---------- ------------ ------------ ---------- ------- -------
  **BOTH GENDERS**                                                                                                                   
  cases (n=630)      983 (78.0)   277 (22.0)   1.00         \[0.83\~1.22\]   0.967      377 (59.8)   229 (36.3)   24 (3.8)   0.01    0.995
  controls (n=535)   834 (77.9)   236 (22.1)   320 (59.8)   194 (36.3)       21 (3.9)                                                
  **MALES**                                                                                                                          
  cases (n=381)      595 (78.1)   167 (21.9)   0.98         \[0.75\~1.27\]   0.885      226 (59.3)   143 (37.5)   12 (3.1)   0.04    0.981
  controls (n=293)   460 (78.5)   126 (21.5)   176 (60.1)   108 (36.9)       9 (3.1)                                                 
  **FEMALES**                                                                                                                        
  cases (n=249)      388 (77.9)   110 (22.1)   1.04         \[0.77\~1.40\]   0.810      151 (60.6)   86 (34.5)    12 (4.8)   0.074   0.967
  controls (n=242)   374 (77.3)   110 (22.7)   144 (59.5)   86 (35.5)        12 (5.0)                                                

CI, confidence interval

3.2. Association between the onset age and the *ANK3* gene rs10761482 polymorphism {#s8b}
----------------------------------------------------------------------------------

As shown in Table 2, there were no differences in either the genotype or the allele frequencies of the *ANK3* rs10761482 polymorphism between the 131 individuals with adolescent-onset schizophrenia and the 499 individuals with adult-onset schizophrenia who successfully completed the genotyping. Stratified analysis revealed similar results by gender: the frequencies of alleles and genotypes between male adolescent-onset and adult-onset patients with schizophrenia were not significantly different, and the frequencies of alleles and genotypes between female adolescent-onset and adult-onset patients were also not significantly different.

###### 

Comparisons of allele and genotype frequencies of the *ANK3* gene rs10761482 polymorphism between persons of Uyghur nationality with adolescent-onset schizophrenia (ADL) and persons of Uyghur nationality with adult-onset schizophrenia (ADU)

  rs10761482          Allele       Genotype                                                                                        
  ------------------- ------------ ------------ ------------ ---------------- ---------- ----------- ----------- --------- ------- -------
  **BOTH GENDERS**                                                                                                                 
  ADL group (n=131)   203 (77.5)   59 (22.5)    0.96         \[0.69\~1.33\]   0.814      77 (58.8)   49 (37.4)   5 (3.8)   0.08    0.960
  ADU group (n=499)   780 (78.2)   218 (21.8)   300 (60.1)   180 (36.1)       19 (3.8)                                             
  **MALES**                                                                                                                        
  ADL group (n=74)    113 (76.4)   35 (23.6)    0.88         \[0.80\~1.35\]   0.570      43 (58.1)   27 (36.5)   4 (5.4)   1.53    0.465
  ADU group (n=307)   482 (78.5)   132 (21.5)   183 (59.6)   116 (37.8)       8 (2.6)                                              
  **FEMALES**                                                                                                                      
  ADL group (n=57)    90 (78.9)    24 (21.1)    1.08         \[0.65\~1.80\]   0.761      34 (59.6)   22 (38.6)   1 (1.8)   1.181   0.405
  ADU group (n=192)   298 (77.6)   86 (22.4)    117 (60.9)   64 (33.3)        11 (5.7)                                             

CI, confidence interval

Separate analyses comparing the 131 adolescentonset patients' results to those of all 535 controls found no difference in allele frequency (*OR*=0.97, *CI*=0.59\~1.45, *p*=0.871) or in genotype frequency (*χ*^2^ =0.06, *p*=0.971). A similar comparison of the 499 adult-onset patients' results to those of all controls found no difference in allele frequency (*OR*=1.01, *CI*=0.82\~1.28, *p*=0.907) or in genotype frequency (*χ*^2^ =0.02, *p*=0.992). These comparisons remained statistically insignificant after stratifying by gender (results provided on request).

4.. Discussion {#s9}
==============

4.1. Main findings {#s9a}
------------------

This study is the first to explore the role of the *ANK3* gene in schizophrenia in a relatively large sample of individuals of Uyghur descent. We found no statistically significant differences between cases and controls in either the allele frequencies or the genotypes of one of the *ANK3* polymorphisms that is most frequently associated with schizophrenia. We also found no link between the *ANK3* rs10761482 polymorphism and the age of onset of schizophrenia. Other studies[@B14] have also failed to replicate findings about the role of *ANK3* in schizophrenia, but the weight of the evidence -- including a meta-analysis[@B11] confirming the role of allele C of the *ANK3* rs10761482 polymorphism and of allele T of the rs10994336 locus -- still supports the hypothesized role of *ANK3* in the pathogenesis of schizophrenia. Several studies have identified mechanisms via which *ANK3* could be involved; for example, allele C of the *ANK3* rs9804190 polymorphism is associated with the down-regulation of mRNA expression in schizophrenia.[@B15] Nevertheless, our negative findings and those of other investigators suggest that other factors may play a role in moderating the effects of *ANK3* .

4.2. Limitations {#s9b}
----------------

Several factors may have contributed to our null findings. (a) The study sample was limited to individuals of the Uyghur minority group in China, a fairly homogenous group (with limited out-group marriage) that has both European and Asian genetic characteristics. Despite the similar C allele frequency of the locus rs10761482 in our sample (78%) to that reported for the European and Asian populations (74.8% and 75%, respectively, based on the PubMed database), the Uyghur group may have unique genetic characteristics that alter the relationship between *ANK3* and schizophrenia. (b) In limiting our sample to individuals with schizophrenia who do not have a family history of mental illness, we may have decreased the relative importance of genetic factors in the group of patients considered in the analysis. (c) We did not assess several other *ANK3* loci that may be related to the pathogenesis of schizophrenia including rs10761482, rs9804190, and rs10994336.[@B11],[@B15] (d) Some studies suggest that genetic polymorphisms are associated with specific clinical subtypes of schizophrenia;[@B16],[@B17] other than considering age of onset, we did not subclassify our results by other potentially important factors. (e) The sample size was too small to justify stratifying results by multiple variables.

4.3. Implications {#s9c}
-----------------

Replication of widely accepted genetic findings about psychiatric illnesses in different, relatively homogenous ethnic groups may help identify factors that moderate the role of these presumed 'universal' genetic factors. Our failure to replicate findings of a relationship between the *ANK3* gene rs10761482 polymorphism and schizophrenia in a relatively large sample of patients with schizophrenia from the Uyghur minority group in western China is an example of the potential promise of such studies. If these results are replicated in further studies, then the focus should change to understanding *why* this widely acknowledged association does not exist in this particular ethnic group. Such follow-up studies would have considerable value in highlighting the genetic environment in which *ANK3* does or does not exert a role in the pathogenesis of schizophrenia.
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